KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Moderna (MRNA) Shares Outstanding (2016 - 2026)

Moderna (MRNA) has disclosed Shares Outstanding for 11 consecutive years, with $397.0 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 2.58% year-over-year to $397.0 million; the TTM value through Mar 2026 reached $397.0 million, up 2.58%, while the annual FY2025 figure was $394.0 million, 2.07% up from the prior year.
  • Shares Outstanding hit $397.0 million in Q1 2026 for Moderna, up from $394.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $400.0 million in Q1 2022 and bottomed at $381.0 million in Q2 2023.
  • Average Shares Outstanding over 5 years is $387.5 million, with a median of $386.0 million recorded in 2024.
  • Year-over-year, Shares Outstanding fell 4.47% in 2022 and then grew 2.58% in 2026.
  • Moderna's Shares Outstanding stood at $385.0 million in 2022, then fell by 0.78% to $382.0 million in 2023, then grew by 1.05% to $386.0 million in 2024, then increased by 2.07% to $394.0 million in 2025, then rose by 0.76% to $397.0 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $397.0 million, $394.0 million, and $391.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.